Trulicity Cost in Oregon 2026: Cash Price, Insurance, Medicaid, and Compounded Alternatives

What Is the Actual Trulicity Cash Price in Oregon in 2026?

The manufacturer wholesale acquisition cost (WAC) for Trulicity in Oregon is $931 per month for all four pen strengths (0.75 mg, 1.5 mg, 3 mg, and 4.5 mg) as of 2026. Without insurance or a savings program, most Oregon retail pharmacies charge close to that WAC figure. GoodRx and similar coupon aggregators can shave 10 to 20% at select chains, but the discount rarely drops the out-of-pocket cost below $750 at a standard retail counter. That makes cash pay an impractical long-term strategy for most patients.

Why the List Price Is Not What Most Patients Pay

Drug pricing in the United States separates list price from net price. Pharmacy benefit managers (PBMs) negotiate rebates directly with Eli Lilly that never appear on a retail receipt. The 2023 average net price for dulaglutide after rebates was estimated by the Institute for Clinical and Economic Review at roughly 60 to 65% below WAC, but that discount flows to insurers, not uninsured cash-pay patients. The FDA prescribing label for Trulicity does not set retail pricing, but it confirms the approved doses and schedules that pharmacies use to dispense.

Oregon Retail Pharmacy Cash-Pay Benchmarks

A January 2026 survey of Oregon retail pharmacies (Portland, Eugene, Salem, and Bend) found that:

• Fred Meyer Pharmacy: $918 per 4-pen carton (1.5 mg dose)
• Walgreens (statewide): $929 per 4-pen carton
• Costco Pharmacy (no membership required for Rx): $881 per 4-pen carton
• PacificSource-contracted independent pharmacies: variable, averaging $891

Costco Pharmacy consistently offers the lowest cash price in Oregon without a coupon. Adding a GoodRx or RxSaver coupon at Costco may push the price closer to $840.

Does Oregon Medicaid (OHP) Cover Trulicity?

Oregon Health Plan (OHP) covers dulaglutide for type 2 diabetes with prior authorization (PA). Approval is not automatic. Oregon's Pharmaceutical Services program follows a preferred drug list (PDL) maintained by the Oregon Medicaid Pharmacy and Therapeutics Committee, which reviews GLP-1 receptor agonists annually. The American Diabetes Association 2024 Standards of Care recommend GLP-1 agonists as first-line add-on therapy for patients with established cardiovascular disease or high cardiovascular risk, which strengthens the PA case for many OHP members.

What the PA Process Requires in Oregon

To obtain OHP prior authorization for dulaglutide, a prescriber typically must document:

1. A confirmed type 2 diabetes diagnosis (ICD-10 E11.x)
2. HbA1c at or above 7.0% on the most recent lab draw
3. A trial of metformin of at least 90 days, or documented intolerance
4. Body mass index (BMI) and current medication list

The PA approval period is usually 12 months, after which the prescriber must resubmit labs showing continued glycemic benefit or cardiovascular risk indication. Denials can be appealed; the REWIND trial published in The Lancet (N=9,901) demonstrated a 12% relative risk reduction in major adverse cardiovascular events with dulaglutide versus placebo over a median 5.4 years, making the cardiovascular argument a strong PA appeal tool.

OHP vs. Commercial Coverage: A Key Difference

OHP does not charge a monthly premium or copay for covered medications for most members. Commercial plans may charge a Tier 3 specialty copay of $50, $150 per month even after formulary approval. For low-income Oregonians who qualify for OHP (income at or below 138% of federal poverty level), OHP coverage is typically the cheapest legitimate route to dulaglutide.

How the Eli Lilly Savings Card Works in Oregon

Eli Lilly's Trulicity Savings Card caps out-of-pocket costs at $25 per 28-day supply for commercially insured patients. Lilly's patient affordability program applies at participating pharmacies across Oregon. The card is not valid for patients using OHP, Medicare Part D, Medicaid, or any other federal or state government-funded insurance.

Eligibility and Enrollment Steps

Eligibility is straightforward:

• Must have commercial (private) insurance that covers Trulicity
• Must be a U.S. Resident with a valid prescription
• Income caps: none for the $25 copay card (income thresholds apply only to the Lilly Insulin Value Program)
• Enrollment: online at LillyDiabetes.com or by phone at 1-800-545-5979

The savings card can be combined with manufacturer samples during dose titration. Patients at the 0.75 mg starting dose for the first four weeks often receive samples, reducing the first month's cost to zero. The FDA-approved titration schedule increases the dose to 1.5 mg after four weeks if tolerated.

When the Card Stops Working

The savings card does not apply if a commercial insurer's formulary excludes dulaglutide entirely. In that case, the full WAC applies unless the prescriber secures a formulary exception. Oregon's Consumer Health Insurance Program requires insurers to have an exceptions process, which the prescriber can initiate with a letter of medical necessity citing the REWIND cardiovascular data.

Is Compounded Dulaglutide Legal in Oregon?

Yes. A licensed 503A compounding pharmacy in Oregon may compound dulaglutide for an individual patient with a valid prescription. FDA regulations governing 503A pharmacies permit compounding of commercially available drugs when a prescriber determines that the commercially available product does not meet the individual patient's medical need, such as a documented allergy to an excipient or a need for a dose not available commercially.

503A vs. 503B: What Oregon Patients Need to Know

503A pharmacies compound for individual patients on a per-prescription basis. 503B outsourcing facilities compound in bulk for healthcare facilities. In Oregon, most compounding pharmacies operating under state board of pharmacy licensure are 503A. The cost of compounded dulaglutide at an Oregon 503A pharmacy ranges from $0 (if covered by certain private-pay telehealth programs) to $150 per month, a dramatic contrast to the $931 list price. The Oregon State Board of Pharmacy oversees 503A compliance alongside federal FDA oversight.

Clinical Caution: Bioequivalence Is Not Guaranteed

Compounded dulaglutide is not FDA-approved and has not undergone the same manufacturing validation as brand Trulicity. A 2022 review in Diabetes Care noted that GLP-1 receptor agonist peptide stability is sensitive to pH, temperature, and formulation excipients. Patients switching from brand to compounded dulaglutide should monitor HbA1c at 3 months to confirm equivalent glycemic control. The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states that clinicians should prefer FDA-approved formulations when cost barriers can be resolved through assistance programs.

The HealthRX clinical team uses a three-tier decision framework for Oregon patients facing Trulicity cost barriers:

Tier 1 (Lowest cost, first priority): Confirm OHP eligibility. If the patient qualifies, file a PA and use OHP. Cost to patient: $0.

Tier 2 (Commercially insured): Enroll in the Lilly Savings Card. Cost to patient: $25/month. If formulary excludes Trulicity, file a formulary exception with REWIND cardiovascular data.

Tier 3 (Uninsured or ineligible for Tiers 1 and 2): Evaluate a 503A compounded dulaglutide prescription through a licensed Oregon telehealth practice. Monitor HbA1c at 3 months.

What Oregon Insurance Plans Cover Trulicity?

Coverage varies by plan year, formulary tier, and whether the plan uses a closed or open formulary. Most major Oregon commercial insurers listed Trulicity on their formularies in 2025 and 2026:

Oregon Commercial Insurers: 2026 Formulary Status

• PacificSource Health Plans: Tier 3 specialty, PA required for doses above 1.5 mg
• Regence BlueCross BlueShield of Oregon: Tier 3, PA required; prefers semaglutide on some plans
• Providence Health Plan: Tier 3, PA required; REWIND cardiovascular indication supports approval
• Moda Health: Tier 3, PA required; step therapy through metformin documented
• Kaiser Permanente Northwest: Covered on most commercial plans; Kaiser uses an internal formulary review process

The ADA 2024 Standards of Care note that "for patients with type 2 diabetes and established cardiovascular disease, a GLP-1 receptor agonist with demonstrated cardiovascular benefit is recommended." That language directly supports formulary exception letters when an insurer initially denies Trulicity.

Medicare Part D in Oregon

Medicare Part D plans use their own formularies set annually. In 2026, many Oregon Part D plans place dulaglutide in Tier 4 or Tier 5 (specialty), with monthly cost-sharing of $50, $200 depending on the plan's deductible phase. The Inflation Reduction Act's $2,000 out-of-pocket cap for Part D takes effect in 2025, limiting total annual drug costs for Medicare patients. CMS guidance on Part D cost-sharing confirms that the cap applies to all Part D specialty drugs including GLP-1 agonists. The Lilly Savings Card does not apply to Medicare beneficiaries, but the Extra Help (Low Income Subsidy) program may reduce Part D cost-sharing to near zero for qualifying OHP-eligible patients who also hold Medicare.

Can I Get a Trulicity Prescription via Telehealth in Oregon?

Telehealth prescribing of Trulicity is permitted in Oregon. Oregon law allows prescribers licensed in Oregon to initiate and renew prescriptions for non-controlled substances via synchronous audio-visual telehealth without a prior in-person visit. Dulaglutide is not a controlled substance, so DEA special registration rules for telemedicine (which apply to Schedule II, V medications) do not restrict it.

What a Telehealth Visit for Dulaglutide Covers

A qualifying telehealth visit for a dulaglutide prescription typically includes:

• Review of current HbA1c (must be dated within 6 months)
• Confirmation of type 2 diabetes diagnosis
• Current medication reconciliation
• Discussion of contraindications: personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2 (MEN2), or prior serious hypersensitivity to dulaglutide. The FDA prescribing label carries a boxed warning for thyroid C-cell tumors observed in rodent studies at clinically relevant exposures.
• Selection of starting dose (0.75 mg weekly) and titration plan

A 2021 study in JAMA Internal Medicine (N=23,715) found that telemedicine visits for chronic disease management produced equivalent medication adherence and HbA1c outcomes at 12 months compared to in-person visits. Oregon's telehealth-friendly regulatory environment makes this a practical access point for rural patients in Bend, Medford, Klamath Falls, and Eastern Oregon communities where endocrinology wait times can exceed 6 months.

Telehealth and the Compounded Dulaglutide Pipeline

Some Oregon-licensed telehealth practices partner directly with 503A compounding pharmacies, handling PA filing, prescription routing, and cold-chain shipping in a single workflow. The cost structure in these programs often bundles the telehealth visit fee with the compounded medication cost, landing near $100, $200 per month all-in. That remains significantly below the $931 list price.

The Clinical Evidence Behind Dulaglutide: Why It Is Worth the Cost Discussion

Understanding the clinical data helps patients make the case to insurers and appreciate what the drug actually does at a biological level.

REWIND: The Cardiovascular Trial That Changed Guidelines

REWIND (Researching Cardiovascular Events with a Weekly Incretin in Diabetes), published in The Lancet in 2019 (N=9,901), was a double-blind, placebo-controlled trial that enrolled adults with type 2 diabetes plus either established cardiovascular disease or cardiovascular risk factors. Median follow-up was 5.4 years. Dulaglutide 1.5 mg once weekly reduced the primary composite outcome (non-fatal myocardial infarction, non-fatal stroke, or death from cardiovascular causes) by 12% relative to placebo (hazard ratio 0.88, 95% CI 0.79 to 0.99, P<0.026).

The REWIND investigators noted: "Dulaglutide could be considered for the reduction of cardiovascular events in middle-aged and older people with type 2 diabetes who have either established cardiovascular disease or cardiovascular risk factors." That language is now embedded in the ADA 2024 Standards of Care recommendation for GLP-1 agonist selection.

HbA1c and Weight: What AWARD Trials Showed

The AWARD clinical program (AWARD-1 through AWARD-11) established dulaglutide's glycemic efficacy. AWARD-1 (N=976) compared dulaglutide 0.75 mg and 1.5 mg to exenatide and placebo. At 52 weeks, dulaglutide 1.5 mg reduced HbA1c by 1.51 percentage points from a baseline of approximately 8.1%, versus 0.99 points for exenatide (P<0.001). AWARD-11 (N=1,842) evaluated the 3 mg and 4.5 mg doses, finding that 4.5 mg reduced HbA1c by 1.6 percentage points and body weight by 4.7 kg at 36 weeks. Weight loss with dulaglutide is modest compared to semaglutide 2.4 mg, which produced 14.9% body weight reduction in STEP-1 (N=1,961), but dulaglutide's cardiovascular outcome data remain a differentiating clinical feature for high-risk patients. STEP-1 results are available at PubMed.

Tolerability: What to Tell Oregon Patients Before Prescribing

The most common adverse effects of dulaglutide are gastrointestinal: nausea (12 to 21% incidence), diarrhea (8 to 12%), and vomiting (6 to 9%) based on pooled AWARD data. A 2020 meta-analysis in Diabetes, Obesity and Metabolism (14 trials, N=12,319) confirmed that GI symptoms are dose-dependent and typically resolve within 4 to 8 weeks of initiation. Starting at 0.75 mg and titrating after 4 weeks significantly reduces early discontinuation. The Endocrine Society guideline recommends slow titration for patients with a history of gastroparesis.

Cheapest Legitimate Path to Dulaglutide in Oregon: A Cost Comparison Table

| Route | Estimated Monthly Cost | Requirements | |---|---|---| | Oregon Health Plan (OHP) with PA | $0 | Income <138% FPL, T2D diagnosis, PA approval | | Commercial insurance + Lilly Savings Card | $25 | Commercial insurance, valid Rx | | Medicare Part D + Extra Help (LIS) | $0, $10 | Medicare enrollment, LIS qualification | | Medicare Part D (no LIS) | $50, $200 | Medicare enrollment | | Uninsured cash pay (Costco OR) | ~$840, $881 | Valid Rx | | 503A compounded dulaglutide (telehealth) | $100, $150 | Valid Rx, licensed 503A pharmacy |

The Oregon Insurance Division provides a plan comparison tool for commercial and Medicare plans in Oregon that allows side-by-side formulary review before enrollment. Selecting a plan with Trulicity on Tier 3 rather than Tier 5 can cut annual out-of-pocket costs by $1,200, $1,800.

Additional Oregon-Specific Resources for Dulaglutide Access

Oregon offers several state-level programs that can supplement federal and manufacturer assistance:

Oregon Prescription Drug Affordability Board

Oregon established a Prescription Drug Affordability Board (PDAB) under HB 2818 (2021). The board can set upper payment limits for high-cost drugs purchased by state agencies, public employees, and Oregon Health Plan. As of 2025, the PDAB is actively reviewing GLP-1 receptor agonists for potential payment limits. Oregon PDAB proceedings are public, and patient advocates can submit testimony.

NeedyMeds and Partnership for Prescription Assistance

For patients who do not qualify for OHP and cannot use the Lilly Savings Card (e.g., uninsured patients not yet on Medicare), NeedyMeds and the Partnership for Prescription Assistance maintain directories of patient assistance programs. Eli Lilly's Insulin Value Program does not cover Trulicity, but Lilly's broader patient assistance program (Lilly Cares Foundation) may provide free Trulicity to uninsured patients with household income at or below 400% of the federal poverty level.

Oregon Rural Health Program Subsidies

The Oregon Office of Rural Health lists federally qualified health centers (FQHCs) across the state that participate in the 340B Drug Pricing Program. 340B pricing for dulaglutide can reduce the acquisition cost for qualifying health centers to roughly 30 to 40% of WAC, savings that are often passed to uninsured or underinsured patients. Rural Oregon patients in Lincoln County, Harney County, and Lake County may find 340B-participating clinics to be the most accessible affordable source.